Dr Reddys Laboratories (RDY) Other Non-Current Assets (2009 - 2026)
Dr Reddys Laboratories (RDY) posted quarterly Other Non-Current Assets of $13.0 million for Q1 2026, up 8.33% year-over-year from $12.0 million in Q1 2025, and up 8.33% quarter-over-quarter from $12.0 million in Q1 2025.
Dr Reddys Laboratories (RDY) Other Non-Current Assets (2009 - 2026) Analysis & Trends
Dr Reddys Laboratories' Other Non-Current Assets history runs 10 years deep, the most recent figure standing at $13.0 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 8.33% year-over-year to $13.0 million; the TTM figure through Mar 2026 stood at $13.0 million (up 8.33% YoY), while the FY2026 annual figure was $13.0 million, up 8.33% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $13.0 million, up from $12.0 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $20.0 million in Q1 2024, with the low at $10.0 million in Q1 2023.
- The 5-year median for Other Non-Current Assets is $12.0 million (2022), against an average of $13.4 million.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets jumped 100.0% in 2024, then tumbled 40.0% in 2025.
- Dr Reddys Laboratories' Other Non-Current Assets stood at $12.0 million in 2022, then fell by 16.67% to $10.0 million in 2023, then surged by 100.0% to $20.0 million in 2024, then sank by 40.0% to $12.0 million in 2025, then climbed by 8.33% to $13.0 million in 2026.
- Business Quant data shows RDY's Other Non-Current Assets at $13.0 million in Q1 2026, $12.0 million in Q1 2025, and $20.0 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 13.00 Mn |
| 10 | Alkermes | 8.19 Bn | 7.53 Bn | 397.90 Mn | 62.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.00 Mn |
| Mar 31, 2025 | 12.00 Mn |
| Mar 31, 2024 | 20.00 Mn |
| Mar 31, 2023 | 10.00 Mn |
| Mar 31, 2022 | 12.00 Mn |
| Mar 31, 2021 | 11.00 Mn |
| Mar 31, 2020 | 11.00 Mn |
| Mar 31, 2019 | 14.00 Mn |
| Mar 31, 2018 | 16.00 Mn |
| Dec 31, 2009 | 4.00 Mn |
| Sep 30, 2009 | 4.00 Mn |
| Jun 30, 2009 | 4.00 Mn |